Tiger Global Is Said to Get $1.6 Billion From Altria’s Juul Deal
(Bloomberg) -- Partners at Tiger Global Management are looking forward to a special holiday bonus this year.
Next week, the U.S. fund will receive a $1.6 billion cash dividend after its portfolio company, electronic cigarette startup Juul Labs Inc., sold 35 percent of itself to tobacco giant Altria Group Inc., according to people familiar with the matter who asked not to be identified because the details are private. Both Juul and Tiger Global declined to comment.
The money is part of Altria's $12.8 billion deal for a minority stake in the company. The tie-up values Juul at $38 billion, making it one of the most highly valued technology startups, surpassing Space Exploration Technologies Corp. and Airbnb Inc.
Following the deal, Juul decided to use a portion of its Altria cash injection to pay dividends to its shareholders and give a cash bonus to its staff, the people said. Employees of Juul Labs will receive about $2 billion in cash bonuses. Shareholders stand to make significantly more.
This morning, Juul Chief Executive Officer Kevin Burns wrote to investors promising them a cash payment of $150 for each share they hold.
Lee Fixel, a partner at Tiger Global, led its roughly $600 million investment in the company earlier this year, said the people. As a result of the dividend payment, the fund will more than double its money, and stands to make considerably more from its stake in the company in the future, because Juul is still privately held.
To contact the reporter on this story: Olivia Zaleski in San Francisco at ozaleski@bloomberg.net
To contact the editors responsible for this story: Jillian Ward at jward56@bloomberg.net, Anne VanderMey
©2018 Bloomberg L.P.
-
Getting To Work Costs Women More | The Reason Why
It is not just about women paying more than men. It is about women paying much more in cities than in villages.
-
AI Bias In Investing Cannot Be Eliminated, But It Can Be Governed
Framing is a particularly important example as identical financial information presented in terms of gains rather than losses can lead an LLM to reach a different assessment.
-
Joining The Dots | Dark Skies, Steady Diya: Why Hope Holds This Diwali
With war, a weak rupee and foreign outflows weighing on sentiment, policymakers at the NDTV World Summit and market veterans at NDTV Profit Ignite: Diwali Edition offered the same advice: stay invested and filter out the noise.
-
The Curious Case of Equitas Small Finance Bank And A CEO Who Quit For Stock
PN Vasudevan believes persistent investor concerns over a perceived conflict of interest had become a governance overhang on Equitas Small Finance Bank's stock, even as the lender improved profitability and asset quality.
-
Talking Points This Week: AI Cash Burn, A Tiger Comeback And An India That Still Finds Its Own Path
India is not immune to higher oil or tighter global liquidity, yet its earnings base is broader, its domestic policy levers are still available.
-
Foreign Investors Own Half Of HDFC Bank and ICICI Bank. An LTCG Cut Could Matter Most Here
Foreign portfolio investors have US$115 billion parked in HDFC Bank, ICICI Bank. If the government cuts long-term capital gains tax, Jefferies says returning foreign money could land here first.
-
'Never Seen This Level Of Negativity': Sandeep Tandon Says The Next Rally May Be Closer Than You Think
Veteran investor Sandeep Tandon says foreign selling is easing, large-caps are due a comeback and mid-caps are crowded, while he turns positive on gold, power and pharma this Diwali.
-
Indians Stay With Family, Not In Hotels | The Reason Why
India still lacks enough clean, reliable and affordable hotels for budget-conscious travellers.
-
The Economic Imperative: Analysing The Material Driving Force Behind India-Canada Strategic Reset
This economic complementarity is further reinforced by deep institutional investment ties and talent mobility, which form the bedrock of the bilateral framework.
-
Medicine Pricing: Where Must Profit Stop?
India must confront excessive margins, hidden incentives and regulatory gaps that threaten the integrity of medicine.